Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status

[News]

New data from the KEYNOTE-756 phase 3 clinical trial show that adding the immunotherapy drug, pembrolizumab, to chemotherapy before and after surgery for breast cancer leads to better outcomes for patients regardless of their age or menopausal status.

More... (https://www.news-medical.net/news/20240320/Pembrolizumab-enhances-breast-cancer-treatment-regardless-of-age-or-menopausal-status.aspx)